Matthew K. Harbaugh

Director, Keenova Therapeutics plc.

Companies

QnityChief financial officer Oct 17, 2025 to Feb 18, 2026¹
NuVasiveChief financial officer Jan 3, 2020 to Sep 5, 2023²
Keenova Therapeutics plcEVP & President, Spec Gen Apr 3, 2019 to Apr 3, 2019³
Keenova Therapeutics plcPresident Jan 4, 2019 to Jan 7, 2019⁴
Keenova Therapeutics plcChief financial officer Jul 2, 2013 to Apr 4, 2018⁵
Keenova Therapeutics plcBoard member Jun 13, 2013 to Jun 13, 2013⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Qnity Q9,292 shares⁷$1.1M at $119.61Nov 1, 2025
NuVasive NUVA0 shares⁸Sep 1, 2023

As of each latest filing. The line shows shares held over time.

Recent filings

Nov 1, 2025Other 9,292 shares of Qnity⁷
Sep 1, 2023Returned to company 11,081 shares of NuVasive⁸
Mar 1, 2023Shares withheld for tax 3,526 shares at $42.67 of NuVasive⁹
Mar 1, 2023Exercised options 12,190 shares of NuVasive⁹
Jan 1, 2023Shares withheld for tax 440 shares at $41.24 of NuVasive¹⁰
Jan 1, 2023Exercised options 1,286 shares of NuVasive¹⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARQnity, Chief financial officer
2
SEC EDGARNuVasive, Chief financial officer
3
SEC EDGARKeenova Therapeutics plc, EVP & President, Spec Gen
4
SEC EDGARKeenova Therapeutics plc, President
5
SEC EDGARKeenova Therapeutics plc, Chief financial officer
6
SEC EDGARKeenova Therapeutics plc, Board member
7
SEC EDGARQnity shares after the filing of Nov 1, 2025
8
SEC EDGARNuVasive shares after the filing of Sep 1, 2023
9
SEC EDGARForm 4 filed Mar 3, 2023
10
SEC EDGARForm 4 filed Jan 3, 2023